Benign prostatic hyperplasia
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. Diagnosed with benign prostatic hyperplasia; 2. Age should be between 50 and 80 years old; 3. Project participants have the ability to make independent decisions, agree to participate in this study, and sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1.Patients diagnosed with prostate cancer; 2.Patients who have used medications within the past 6 months that may affect prostate volume, International Prostate Symptom Score (IPSS), Quality of Life (QoL) score (0-6), International Consultation on Incontinence Questionnaire-Male Lower Urinary Tract Symptoms (ICIQ-MLUTS), or voiding diary results (including but not limited to 5a-reductase inhibitors, a-blockers, M-receptor antagonists, herbal preparations, traditional Chinese medicines, or Chinese patent drugs); 3.Patients who have used medications within the past 6 months that may influence sex hormone metabolome levels (including but not limited to testosterone undecanoate formulations or gels, dihydrotestosterone formulations or gels, endocrine therapy drugs for prostate cancer, estrogen formulations or gels, or traditional Chinese medicines or Chinese patent drugs for kidney tonification and yang enhancement); 4.Patients with congenital abnormalities of the reproductive system; 5.Patients with genital infections, acute urinary tract infections, or prostatitis; 6.Patients with steroid hormone-related endocrine disorders; 7.Patients currently taking psychotropic or neurological medications; 8.Patients with positive HIV or syphilis test results; 9.Patients with abnormal liver or kidney function (total bilirubin >17.1 µmol/L; creatinine >176.8 µmol/L); 10.Patients deemed by the investigator unsuitable for participation in the study;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| prostate volume;QoL score;IPSS score;ICIQ-MLUTS; | — |
Countries
China
Contacts
Peking University Shenzhen Hospital